A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men

Milton L. Wainberg, Frederick Muench, Jon Morgenstern, Eric Hollander, Thomas W. Irwin, Jeffrey T. Parsons, Andrea Allen, Ann O'Leary

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Objective: Compulsive sexual behavior (CSB) is a condition characterized by loss of control over sexual behavior and repeated negative consequences, including unsafe sex. Selective serotonin reuptake inhibitors have been found to reduce CSB symptomatology in open-label trials. The objective of this study was to conduct a preliminary double-blind, placebo-controlled evaluation of the efficacy, acceptability, and tolerability of citalopram in the treatment of CSB. Method: Twenty-eight men who have sex with men who met the threshold for CSB on the basis of existing validated measures participated in a 12-week, double-blind trial of citalopram 20 to 60 mg/day to evaluate its effects on CSB symptoms. The primary efficacy measure was the Yale-Brown Obsessive Compulsive Scale-Compulsive Sexual Behavior. The study was conducted from June 2002 to April 2004. Results: Significant treatment effects were obtained for sexual desire/drive (p < .05) and frequency of masturbation (p < .01) and pornography use (p < .05). Both groups reduced sexual risk, but did not differ significantly. Conclusions: This study provides partial support for the effectiveness of citalopram for reducing symptoms of CSB in this population. Larger-scale trials are recommended to determine the public health benefits of this treatment.

Original languageEnglish (US)
Pages (from-to)1968-1973
Number of pages6
JournalJournal of Clinical Psychiatry
Volume67
Issue number12
StatePublished - Dec 2006
Externally publishedYes

Fingerprint

Compulsive Behavior
Citalopram
Double-Blind Method
Sexual Behavior
Placebos
Therapeutics
Erotica
Masturbation
Unsafe Sex
Sexual Minorities
Serotonin Uptake Inhibitors
Insurance Benefits
Public Health

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Wainberg, M. L., Muench, F., Morgenstern, J., Hollander, E., Irwin, T. W., Parsons, J. T., ... O'Leary, A. (2006). A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men. Journal of Clinical Psychiatry, 67(12), 1968-1973.

A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men. / Wainberg, Milton L.; Muench, Frederick; Morgenstern, Jon; Hollander, Eric; Irwin, Thomas W.; Parsons, Jeffrey T.; Allen, Andrea; O'Leary, Ann.

In: Journal of Clinical Psychiatry, Vol. 67, No. 12, 12.2006, p. 1968-1973.

Research output: Contribution to journalArticle

Wainberg, ML, Muench, F, Morgenstern, J, Hollander, E, Irwin, TW, Parsons, JT, Allen, A & O'Leary, A 2006, 'A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men', Journal of Clinical Psychiatry, vol. 67, no. 12, pp. 1968-1973.
Wainberg, Milton L. ; Muench, Frederick ; Morgenstern, Jon ; Hollander, Eric ; Irwin, Thomas W. ; Parsons, Jeffrey T. ; Allen, Andrea ; O'Leary, Ann. / A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men. In: Journal of Clinical Psychiatry. 2006 ; Vol. 67, No. 12. pp. 1968-1973.
@article{def2465e7cbb47c590675e6b557d31e4,
title = "A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men",
abstract = "Objective: Compulsive sexual behavior (CSB) is a condition characterized by loss of control over sexual behavior and repeated negative consequences, including unsafe sex. Selective serotonin reuptake inhibitors have been found to reduce CSB symptomatology in open-label trials. The objective of this study was to conduct a preliminary double-blind, placebo-controlled evaluation of the efficacy, acceptability, and tolerability of citalopram in the treatment of CSB. Method: Twenty-eight men who have sex with men who met the threshold for CSB on the basis of existing validated measures participated in a 12-week, double-blind trial of citalopram 20 to 60 mg/day to evaluate its effects on CSB symptoms. The primary efficacy measure was the Yale-Brown Obsessive Compulsive Scale-Compulsive Sexual Behavior. The study was conducted from June 2002 to April 2004. Results: Significant treatment effects were obtained for sexual desire/drive (p < .05) and frequency of masturbation (p < .01) and pornography use (p < .05). Both groups reduced sexual risk, but did not differ significantly. Conclusions: This study provides partial support for the effectiveness of citalopram for reducing symptoms of CSB in this population. Larger-scale trials are recommended to determine the public health benefits of this treatment.",
author = "Wainberg, {Milton L.} and Frederick Muench and Jon Morgenstern and Eric Hollander and Irwin, {Thomas W.} and Parsons, {Jeffrey T.} and Andrea Allen and Ann O'Leary",
year = "2006",
month = "12",
language = "English (US)",
volume = "67",
pages = "1968--1973",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "12",

}

TY - JOUR

T1 - A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men

AU - Wainberg, Milton L.

AU - Muench, Frederick

AU - Morgenstern, Jon

AU - Hollander, Eric

AU - Irwin, Thomas W.

AU - Parsons, Jeffrey T.

AU - Allen, Andrea

AU - O'Leary, Ann

PY - 2006/12

Y1 - 2006/12

N2 - Objective: Compulsive sexual behavior (CSB) is a condition characterized by loss of control over sexual behavior and repeated negative consequences, including unsafe sex. Selective serotonin reuptake inhibitors have been found to reduce CSB symptomatology in open-label trials. The objective of this study was to conduct a preliminary double-blind, placebo-controlled evaluation of the efficacy, acceptability, and tolerability of citalopram in the treatment of CSB. Method: Twenty-eight men who have sex with men who met the threshold for CSB on the basis of existing validated measures participated in a 12-week, double-blind trial of citalopram 20 to 60 mg/day to evaluate its effects on CSB symptoms. The primary efficacy measure was the Yale-Brown Obsessive Compulsive Scale-Compulsive Sexual Behavior. The study was conducted from June 2002 to April 2004. Results: Significant treatment effects were obtained for sexual desire/drive (p < .05) and frequency of masturbation (p < .01) and pornography use (p < .05). Both groups reduced sexual risk, but did not differ significantly. Conclusions: This study provides partial support for the effectiveness of citalopram for reducing symptoms of CSB in this population. Larger-scale trials are recommended to determine the public health benefits of this treatment.

AB - Objective: Compulsive sexual behavior (CSB) is a condition characterized by loss of control over sexual behavior and repeated negative consequences, including unsafe sex. Selective serotonin reuptake inhibitors have been found to reduce CSB symptomatology in open-label trials. The objective of this study was to conduct a preliminary double-blind, placebo-controlled evaluation of the efficacy, acceptability, and tolerability of citalopram in the treatment of CSB. Method: Twenty-eight men who have sex with men who met the threshold for CSB on the basis of existing validated measures participated in a 12-week, double-blind trial of citalopram 20 to 60 mg/day to evaluate its effects on CSB symptoms. The primary efficacy measure was the Yale-Brown Obsessive Compulsive Scale-Compulsive Sexual Behavior. The study was conducted from June 2002 to April 2004. Results: Significant treatment effects were obtained for sexual desire/drive (p < .05) and frequency of masturbation (p < .01) and pornography use (p < .05). Both groups reduced sexual risk, but did not differ significantly. Conclusions: This study provides partial support for the effectiveness of citalopram for reducing symptoms of CSB in this population. Larger-scale trials are recommended to determine the public health benefits of this treatment.

UR - http://www.scopus.com/inward/record.url?scp=33845983638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845983638&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 1968

EP - 1973

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 12

ER -